U.S. Clinical Oncology Next Generation Sequencing Market

Name: U.S. Clinical Oncology Next Generation Sequencing Market
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The clinical oncology next generation sequencing market in the United States is expected to reach a projected revenue of US$ 711.8 million by 2033. A compound annual growth rate of 16.03% is expected of the United States clinical oncology next generation sequencing market from 2026 to 2033.

Biotechnology
- Sequencing technology
  - clinical oncology next generation sequencing ngs market

U.S. clinical oncology next generation sequencing ngs technology outlook (Revenue, USD million, 2021-2033)
- Whole Exome Sequencing
- Targeted Sequencing and Resequencing
- Whole Genome Sequencing
U.S. clinical oncology next generation sequencing ngs workflow outlook (Revenue, USD million, 2021-2033)
- NGS Pre-Sequencing
- NGS Data Analysis
- NGS Sequencing
U.S. clinical oncology next generation sequencing ngs application outlook (Revenue, USD million, 2021-2033)
- Screening
  - Sporadic Cancer
  - Inherited Cancer
- Companion Diagnostics
- Others
U.S. clinical oncology next generation sequencing ngs end use outlook (Revenue, USD million, 2021-2033)
- Hospitals
- Clinics
- Laboratories

U.S. Clinical Oncology Next Generation Sequencing Market

Data Tree

Sign up - it's easy, and free!